Hoth Therapeutics Expands Clinical Trial to Combat Severe Skin Reactions in Cancer Treatments

Hoth Therapeutics Expands Clinical Trial to Address Severe Skin Reactions in Cancer Patients

In a significant development for cancer care, Hoth Therapeutics, Inc. announces an expansion of its CLEER-001 Phase 2a clinical trial with the addition of a new enrolling site at Regis Clinical Research in Miami, Florida. This expansion responds to heightened patient demand for HT-001, a therapeutic intervention designed to alleviate severe skin toxicities often associated with epidermal growth factor receptor (EGFR) inhibitor therapies. This condition, which impacts approximately 200,000 Americans annually, can lead to reductions or discontinuations of treatment in nearly one-third of patients, underscoring the critical need for effective management strategies.

Initial results from the CLEER-001 trial indicate promising efficacy of HT-001, with data revealing that 100% of participants in the open-label cohort manage to maintain an ARIGA rash severity score of ≤1 by week six. Notably, none of the patients required dose reductions or interrupted their EGFR inhibitor therapies while receiving HT-001. These findings are particularly significant given the precedent of highly debilitating side effects that can severely compromise treatment adherence and overall patient quality of life. Furthermore, more than 65% of trial participants report substantial reductions in discomfort associated with pain and itching, with no observations of dose-limiting toxicities during the trial period.

Robb Knie, CEO of Hoth Therapeutics, highlights the urgency behind this expansion, stating that the rising demand for patient enrollment necessitated the addition of the Miami site to expedite the collection of comprehensive trial data and enhance the company’s regulatory timeline. The successful navigation of regulatory pathways is crucial for Hoth Therapeutics, especially considering that there are currently no FDA-approved treatments specifically targeting the severe skin reactions caused by EGFR therapies. A recent case study showcased at the American Academy of Dermatology Annual Meeting illustrates the potential of HT-001, documenting complete resolution of symptoms in a patient with metastatic breast cancer within just one week of initiating treatment. As the landscape of cancer treatment continues to evolve, Hoth's efforts stand to transform patient experiences and outcomes in this area of care.

In the wake of this expansion, patients and healthcare providers interested in the CLEER-001 trial can access more information through Regis Clinical Research's dedicated channels. Hoth Therapeutics aims to facilitate improved treatment options for individuals facing debilitating skin conditions while undergoing critical cancer therapies, marking a significant step forward in oncology care.